Show simple item record

dc.contributor.authorWhelan, S.
dc.contributor.authorKarim, C.
dc.contributor.authorYe, J.
dc.contributor.authorIngallinera, T.
dc.contributor.authorCherala, G.
dc.contributor.authorJameson, K.
dc.contributor.authorWilliams, A.
dc.contributor.authorSharp, A.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorPacey, S.
dc.contributor.authorBlagden, S.
dc.contributor.authorPlummer, R.
dc.contributor.authorHochhauser, D.
dc.contributor.authorEvans, J.
dc.contributor.authorDe Bono, J.
dc.contributor.authorPowers, J.
dc.date.accessioned2023-05-17T09:50:55Z
dc.date.available2023-05-17T09:50:55Z
dc.date.issued2022en
dc.identifier.citationWhelan S, Karim C, Ye J, Ingallinera T, Cherala G, Jameson K, et al. Initial Clinical Characterization of Novel Proximal Biomarkers for Nx-1607, a First-Inclass Oral Cbl-B Inhibitor, in Patients with Advanced Malignancies. Journal for immunotherapy of cancer. 2022 Nov;10:A809-A. PubMed PMID: WOS:000919423400733.en
dc.identifier.doi10.1136/jitc-2022-SITC2022.0777en
dc.identifier.urihttp://hdl.handle.net/10541/626279
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1136/jitc-2022-SITC2022.0777en
dc.titleInitial clinical characterization of novel proximal biomarkers for Nx-1607, a first-inclass oral Cbl-B inhibitor, in patients with advanced malignanciesen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentNurix Therapeutics, Inc., San Francisco, CA,en
dc.identifier.journalJournal for Immunotherapy of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record